Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Patient feedback information is available for physicians employed by Rush University Medical Center who have received
30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
My focus is in patients with types of blood cancers, particularly patients with leukemia, lymphoma and multiple myeloma. I work within the subspecialty of hematology called bone marrow transplant, and what we do is offer therapy using cells to treat diseases that may be resistant to traditional chemotherapy. We also treat patients with this type of therapy if their disease is very aggressive or thought to be not curable with just the traditional forms of chemotherapy.
Many years ago, when the first transplants were being done, the candidates for this procedure were quite limited because of the way the patient has side effects from the high doses of chemotherapy — and in some cases radiation therapy — that we used to treat their disease. But now, we’re able to offer a wider range of therapies to a wider range of patients. Patients who may have not been candidates in the past are now able to receive less intense types of high-dose chemotherapy that still give them the benefit of a bone marrow transplant.